Loading...
Loading...
Oramed Pharmaceuticals
ORMP announced today that it has received allowance for a key patent from the Israeli Patent Office. The patent, entitled "Methods and Compositions for Oral Administration of Exenatide," covers oral exenatide compositions made using the company's proprietary technology.
Exenatide, a GLP-1 analog, is currently only marketed in injectable form, and is indicated for the treatment of Type 2 diabetes. Exenatide has an excellent safety profile and a plethora of positive medicinal effects including weight loss and improved pancreatic cell function.
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in